Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Rosacea Clinical Trial

Official title:

Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01134991
• Other study ID #: 0041-10LND /FX2010-02
• Status: Terminated
• Phase: Phase 2
• First received: May 26, 2010
• Last updated: August 25, 2015
• Start date: June 2010

Study information

• Verified date: August 2010
• Source: Foamix Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Institutional Review Board - Laniado Hospital
• Study type: Interventional

Clinical Trial Summary

Acne rosacea is a chronic acneiform disorder affecting both the skin and the eye. It is a syndrome of undetermined etiology characterized by both vascular and papulopustular components involving the face and occasionally the neck and upper trunk.

This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in moderate to severe Rosacea patients.

Description:

A Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study. The study will involve three treatment groups. Eligible patients will be randomized to receive either FXFM244 - 1%, FXFM244 - 4% or Placebo, in a blinded fashion. Patients will be treated twice daily for 12 weeks. Following the screening period and baseline visit, study subjects will return at Weeks 3, 6, 9 and 12. A follow up visit will take place at week 16. At each visit, patients will be evaluated via lesion count, global assessment tolerability and safety.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with clinical diagnosis of moderate to severe facial rosacea as determined by:

• At least 8 but no more than 50 total papules and/or pustules (inflammatory lesions)

• Presence of moderate to severe erythema

• Presence of telangiectasia.

• An Overall Rosacea Severity score =2.5

2. Patient is male or female over 18 years of age.

3. No known medical conditions that, in the Investigator's opinion could interfere with study participation

4. Patient is willing and able to comply with all requirement of the protocol

5. Patient is willing and able to give written informed consent prior to participation in the study

Exclusion Criteria:

1. Presence of skin diseases at or near the investigational area

2. Immunosuppressed state or other serious systemic disease

3. Signs and/or symptoms of systemic infection

4. Concomitant medication:

• Use of oral and/or topical antibiotic treatment within 14 days prior to study entry.

• Use of any topical anti-rosacea agent except antibiotics within 14 days prior to study entry.

• Use of cyproterone acetate, CPA-containing contraceptives (e.g. Diane) or other corticosteroids (during the last 3 months);

• Use of retinoids (during the last 4 weeks)

5. Use of artificial sun bath or having a sun holiday during the last 2 weeks

6. Alcohol or drug abuse, according to assessment by the investigator

7. Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication

8. Use of another investigational drug within 30 days prior to entry into this study

9. Pregnant or lactating women.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rosacea

Intervention

Drug:
• Topical Minocycline Foam FXFM244
FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks

Locations

Country	Name	City	State
Israel	Sourasky Medical Center	Tel-Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Foamix Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in signs and symptoms of rosacea		12 weeks	Yes
Secondary	The severity of the overall rosacea condition will be measured at baseline and at all follow-up visits. The severity will be assessed and graded based on the scales for erythema, telangiectases and number of papulopustular lesions		0, 3, 6, 9 and 12 weeks	Yes